The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
FORM D

OMB APPROVAL OMB Number: 3235-0076 Estimated average burden hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
	Dravious		
CIK (Filer ID Number)	Previous Names	X None	Entity Type
0001806310			X Corporation
Name of Issuer			Limited Partnership
Taysha Gene Therapies, Inc.			Limited Liability Company
Jurisdiction of Incorporation/Org	ganization		General Partnership
DELAWARE			Business Trust
Year of Incorporation/Organizat	ion		
Over Five Years Ago			Other (Specify)
X Within Last Five Years (Spe	ecify Year) 2020		
Yet to Be Formed			
2. Principal Place of Business	and Contact Information		
Name of Issuer			
Taysha Gene Therapies, Inc.			
Street Address 1		Street Address 2	
3000 PEGASUS PARK DRIVE		SUITE 1430	
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
DALLAS	TEXAS	75247	(214) 612-0000
3. Related Persons			
Last Name	First Name		Middle Name
Session II	RA		
Street Address 1	Street Address 2		
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Co	ountry	ZIP/PostalCode
Dallas	TEXAS		75247
Relationship: X Executive Offi	cer X Director Promoter		
Clarification of Response (if Neo	cessary):		
Last Name	First Name		Middle Name
Manning	Paul		B.
Street Address 1	Street Address 2		D.
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Co	ountry	ZIP/PostalCode
Dallas	TEXAS	, and y	75247
	cer X Director Promoter		
Clarification of Response (if Nec			
,			
Last Name	First Name		Middle Name
Nolan	Sean		P.
Street Address 1	Street Address 2		
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Co	ountry	ZIP/PostalCode
Dallas	TEXAS		75247
Relationship: Executive Office	cer X Director Promoter		

Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Donenberg	Phillip	B.	
Street Address 1	Street Address 2		
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Country	ZIP/PostalCode	
Dallas	TEXAS	75247	
Relationship: Executive Officer			
Clarification of Response (if Neces	esary):		
Last Name	First Name	Middle Name	
Nagendran Nagendran	First Name Sukumar	WINGUIG WATTE	
Street Address 1	Street Address 2		
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Country	ZIP/PostalCode	
Dallas	TEXAS	75247	
		15241	
. Ш			
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Reape	Kathleen		
Street Address 1	Street Address 2		
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Country	ZIP/PostalCode	
Dallas	TEXAS	75247	
Relationship: Executive Officer	X Director Promoter		
Clarification of Response (if Neces	esary):		
Last Name	First Name	Middle Name	
Sepp-Lorenzino	Laura		
Street Address 1	Street Address 2		
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Country	ZIP/PostalCode	
Dallas	TEXAS	75247	
Relationship: Executive Officer			
Clarification of Response (if Neces	ssary):		
Last Name	First Name	Middle Name	
Prasad	Suyash		
Street Address 1	Street Address 2		
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Country	ZIP/PostalCode	
Dallas	TEXAS	75247	
Relationship: X Executive Office	r Director Promoter		
Clarification of Response (if Neces	esary):		
Last Name	First Name	Middle Name	
Alam	Kamran		
Street Address 1	Street Address 2		
3000 Pegasus Park Drive	Suite 1430		
City	State/Province/Country	ZIP/PostalCode	
Dallas	TEXAS	75247	
Relationship: X Executive Office	r Director Promoter		
Clarification of Response (if Neces	ssary):		
4. Industry Group			

Agriculture	Health Care	Retailing			
Banking & Financial Services	X Biotechnology	Restaurants			
Commercial Banking	Health Insurance				
Insurance	Ulassitala 8 Dhuaisiana	Technology			
Investing	Hospitals & Physicians	Computers			
Investment Banking	Pharmaceuticals	Telecommunications			
Pooled Investment Fund	Other Health Care	Other Technology			
Is the issuer registered as	Manufacturing	Travel			
an investment company under the Investment Company	Real Estate	Airlines & Airports			
Act of 1940?	Commercial	Lodging & Conventions			
∐Yes ∐No	Construction	Tourism & Travel Services			
Other Banking & Financial Services	REITS & Finance	Other Travel			
Business Services	Residential	Other			
Energy	Other Real Estate	_ out.			
Coal Mining					
Electric Utilities					
Energy Conservation					
Environmental Services					
Oil & Gas					
Other Energy					
5. Issuer Size					
Revenue Range OR	Aggregate Net Asset Va	alue Range			
No Revenues	No Aggregate Net As	sset Value			
\$1 - \$1,000,000	\$1 - \$5,000,000				
\$1,000,001 - \$5,000,000	\$5,000,001 - \$25,000	0,000			
\$5,000,001 - \$25,000,000	\$25,000,001 - \$50,00	000,000			
\$25,000,001 -					
\$100,000,000	\$50,000,001 - \$100,0	000;000			
Over \$100,000,000	Over \$100,000,000				
X Decline to Disclose	Decline to Disclose				
Not Applicable	Not Applicable				
6. Federal Exemption(s) and Exclusion(s) Cla	imed (select all that apply)				
	Investment Comp	any Act Section 2(a)			
		any Act Section 3(c)			
Rule 504(b)(1) (not (i), (ii) or (iii))	Section 3(c)(1)	Section 3(c)(9)			
Rule 504 (b)(1)(i)	Section 3(c)(2)	Section 3(c)(10)			
Rule 504 (b)(1)(ii)	Section 3(c)(3)	Section 3(c)(11)			
Rule 504 (b)(1)(iii)					
X Rule 506(b)	Section 3(c)(4)	Section 3(c)(12)			
Rule 506(c)	Section 3(c)(5)	Section 3(c)(13)			
Securities Act Section 4(a)(5)	Section 3(c)(6)	Section 3(c)(14)			
_	Section 3(c)(7)				
7. Type of Filing					
X New Notice Date of First Sale 2022-10-21	First Sale Yet to Occur				
Amendment	First Sale Tet to Occur				
8. Duration of Offering					
Does the Issuer intend this offering to last more	than one year? Yes X	No			
9. Type(s) of Securities Offered (select all that apply)					

X Equity	Pooled Investment Fund Interests
Debt	Tenant-in-Common Securities
Option, Warrant or Other Right to Acquire Another Security	Mineral Property Securities
Security to be Acquired Upon Exercise of Option, Warrant or C	Other (describe)
Right to Acquire Security	
10. Business Combination Transaction	
Is this offering being made in connection with a business combination	tion transaction, such as a
merger, acquisition or exchange offer?	Yes X No
Clarification of Response (if Necessary):	
11. Minimum Investment	
Minimum investment accepted from any outside investor \$0 USD	
12. Sales Compensation	
Recipient	Recipient CRD Number X None
	(Associated) Broker or Dealer CRD Number X None
	Street Address 2
	State/Province/Country ZIP/Postal Code
State(s) of Solicitation (select all that apply) All States	Foreign/non-US
Check "All States" or check individual States	
13. Offering and Sales Amounts	
Total Offering Amount \$30,000,000 USD or ☐ Indefinite	
Total Amount Sold \$30,000,000 USD	
Total Remaining to be Sold \$0 USD or Indefinite	
Total Nemaning to be dold \$\psi_0 \cdot \c	
Clarification of Response (if Necessary):	
14. Investors	
Select if securities in the offering have been or may be sold to	persons who do not qualify as accredited investors, and
enter the number of such non-accredited investors who alread	
Regardless of whether securities in the offering have been or investors, enter the total number of investors who already hav	
	- Invoced in the offering.
15. Sales Commissions & Finder's Fees Expenses	
Provide separately the amounts of sales commissions and finders an estimate and check the box next to the amount.	fees expenses, if any. If the amount of an expenditure is not known, provide
Sales Commissions \$0 USD Estimate	
Finders' Fees \$0 USD Estimate	
Clarification of Response (if Necessary):	
16. Use of Proceeds	
	peen or is proposed to be used for payments to any of the persons required to be to Item 3 above. If the amount is unknown, provide an estimate and check
\$0 USD Estimate	
Clarification of Response (if Necessary):	
Signature and Submission	
Please verify the information you have entered and review the to file this notice.	Terms of Submission below before signing and clicking SUBMIT below
T (0.1.1.1.1	

Terms of Submission

In submitting this notice, each issuer named above is:

• Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*

- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Taysha Gene Therapies, Inc.	/s/ Kamran Alam	Kamran Alam	Chief Financial Officer	2022-11-07

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.